24 min listen
A Belief that Early Interventions Will Be the Key to Treating Alzheimer’s Disease
FromThe Bio Report
ratings:
Length:
36 minutes
Released:
Oct 31, 2019
Format:
Podcast episode
Description
Efforts to develop effective therapies to treat Alzheimer’s disease have been stymied by a long history of clinical failures. Those disappointments have included two, late-stage failures of AC Immune’ Crenezumab, which the company is developing with it partner Roche. The two companies are continuing to pursue the drug under the belief that treating patients earlier in the progress of the disease will be critical. We spoke to Andrea Pfeifer, CEO of AC Immune, about the company’s efforts to identify and treat Alzheimer’s at its earliest stages, its efforts to develop a vaccine against the condition, and why she believes the future of Alzheimer care will involve combination therapies similar to what has emerged in the area of cancer.
Released:
Oct 31, 2019
Format:
Podcast episode
Titles in the series (100)
International Collaboration Seeks to Drive Breakthroughs in Progressive MS: There has been dramatic progress in the understanding and treatment of relapsing remitting multiple sclerosis, a debilitating neurodegenerative disorder. But progressive MS, a more advanced form of the disease, has remained elusive. Now, a novel coll... by The Bio Report